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ABSTRACT 27 
The global spread of the 2009 pandemic H1N1 (pH1N1) virus in humans increases the likelihood 28 
that this influenza virus strain could undergo antigenic drift in the coming years. Previous seasonal 29 
H1N1 and H3N2 influenza strains acquired additional glycosylations in the globular head of their 30 
hemagglutinin (HA) proteins as they evolved over time; these are believed to shield antigenically 31 
relevant regions. We used influenza A/Netherlands/602/2009 recombinant (rpH1N1) viruses to 32 
which we added additional HA glycosylation sites reflecting their temporal appearance in previous 33 
seasonal H1N1 viruses. Additional glycosylations resulted in substantial attenuation in mice and 34 
ferrets, while deleting HA glycosylation sites from a pre-pandemic 1991 seasonal H1N1 influenza 35 
virus resulted in increased pathogenicity in mice. Sera from mice infected with wild type (WT) 36 
rpH1N1 virus showed a considerable loss of HA inhibitory (HI) activity against rpH1N1viruses 37 
glycosylated at sites 144 or 144-172, indicating that the polyclonal antibody response elicited by 38 
WT rpH1N1 HA seems to be directed against an immunodominant region, likely site Sa, shielded 39 
by glycosylation at 144. Sera from humans vaccinated with the pH1N1 inactivated vaccine also 40 
showed reduced activity against the 144 and 144-172 mutant viruses. Remarkably, the HI activity of 41 
sera from virus-infected mice demonstrated that glycosylation at position 144 resulted in the 42 
induction of a broader polyclonal response able to cross-neutralize all WT and glycosylation mutant 43 
pH1N1 viruses. Mice infected with a recent seasonal virus in which glycosylation sites 71, 142 and 44 
177 were removed, elicited antibodies that protected against challenge with the antigenically distant 45 
pH1N1 virus. Thus, acquisition of glycosylation sites in the HA of H1N1 human influenza viruses 46 
not only affects their pathogenicity and ability to escape from polyclonal antibodies elicited by 47 
previous influenza virus strains, but also their ability to induce cross-reactive antibodies against 48 
drifted antigenic variants. These findings provide the basis for designing improved vaccines and 49 
immunization strategies capable of protecting against a broader range of influenza virus strains. 50 
51 
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MAIN TEXT 52 
Introduction 53 
Influenza A virus infections remain a major concern causing a substantial burden to public health, 54 
with estimated annual medical costs of approximately $10.4 billion dollars in the US (1). The 55 
emergence of the 2009 pandemic H1N1 (pH1N1) virus provided the first direct evidence that 56 
previously circulating subtypes, given enough time, can cause a novel pandemic due to the 57 
increased proportion of the human population being naïve to the hemagglutinin (HA) of this new 58 
strain (a re-emerging subtype) (2). Thus, the level and quality of cross-protective HA antibodies 59 
play an important role in determining the pandemic potential of a novel influenza A virus strain. 60 
 61 
We and others have previously demonstrated that the HA of the 2009 pH1N1 strain shares antigenic 62 
similarities to the HA of human H1N1 viruses that circulated prior to 1950, including substantial 63 
homology to the 1918 virus (3-6), specifically around antigenic site Sa (3, 7, 8). In contrast, 64 
vaccination (3, 6) or infection (4) with contemporary seasonal H1N1 strains induces little or no 65 
cross-reactivity to the 2009 pH1N1 virus, which correlates with a greater difference at the amino 66 
acid level seen at or near the known antigenic sites located in the globular head of the HA (3). 67 
 68 
Previous seasonal H1N1 and H3N2 influenza viruses circulating in humans have been shown to 69 
undergo antigenic drift (a gradual accumulation of amino acid changes in or around the HA 70 
antigenic sites) due to immune selection pressure. Some of these residue changes resulted in the 71 
acquisition of glycosylation sites in the HA, some of which are maintained, while others are 72 
replaced or disappear over time, suggesting that HA glycosylation plays an important evolutionary 73 
role in human influenza A viruses (9-11). Recent studies have shown that HA glycosylation can 74 
affect the antigenic and receptor binding properties of this viral protein (12), as well as the virulence 75 
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of influenza viruses (13-15). Of interest, a number of glycosylation sites on the globular head of the 76 
HA were temporally acquired from 1918 to 2009 by the seasonal H1N1 viruses and most of these 77 
are located within or near antigenic site Sa (9-11). In contrast, the 2009 pH1N1 virus lacks these 78 
additional glycosylation sites and shares the same glycosylation pattern as the 1918 H1N1 pandemic 79 
virus. Importantly, the HA glycosylations acquired by the seasonal H1N1 viruses have been 80 
proposed to shield antigenic sites from antibody mediated neutralization and to be an important 81 
factor influencing the serum cross-reactivity seen in the general population between the recently 82 
extinguished seasonal H1N1 viruses and the 2009 pH1N1 and 1918 pandemic viruses (6, 16, 17). 83 
However, the specific role that each of the H1 glycosylation sites plays in the virulence and 84 
antigenic properties of the 2009 pH1N1 has not been addressed. 85 
 86 
The 2009 pH1N1 strain has spread globally since its original outbreak in North America, and it is 87 
now circulating seasonally in the Northern and Southern hemispheres, replacing the previous H1N1 88 
viruses. It is expected that the pH1N1 virus will start to undergo antigenic drift driven by immune 89 
selection pressure. Acquisition of glycosylations might contribute to the emergence of H1N1 drift 90 
variants. In this study we investigated the specific effects of the acquisition of glycosylations in the 91 
globular head of the H1N1 HA on virulence and antigenic properties of H1N1viruses. Our results 92 
indicate that HA glycosylation plays a crucial role in both pathogenesis and in escape from pre-93 
existing immunity, as well as in induction of cross-reactive polyclonal antibody responses.94 
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Results 95 
H1N1 human viruses acquired glycosylation sites in the globular head of the HA protein over 96 
time. 97 
A complete analysis of the amino acid sequence of the 1918 and the 2009 H1N1 pandemic viruses 98 
revealed that the HA1 of these viruses are putatively glycosylated at the same sites. On the other 99 
hand, the 2009 H1N1 HA protein showed distinct antigenic properties with respect to previously 100 
circulating seasonal H1N1 strains. To better understand the differences that might be responsible for 101 
these different properties, we focused our analysis on the amino acid sequences around the known 102 
antigenic sites. Sequence alignments revealed that since the introduction of the H1N1 viruses into 103 
humans in 1918, a number of glycosylation sites, as predicted by the motif N-X-S/T, have been 104 
acquired in the HA globular head over time (Fig. 1). Of interest, these glycosylation sites appeared 105 
predominantly near or within antigenic site Sa (Fig. 1). Although there are no sequences available 106 
of human influenza viruses between 1918 and 1933, and with the caveat that most of the sequences 107 
from early H1N1 viruses are from strains that have been passaged extensively in eggs and/or 108 
nonhuman mammalian laboratory cell cultures, it appears that during the years 1935 to 1957, three 109 
different HA glycosylations were acquired sequentially (at amino acid residues 144, 172 and 177 110 
[H3 numbering: 130, 158 and 163, respectively], highlighted in Fig. 1 and 2) that were consistently 111 
found in human isolates. The emergence of the H2N2 pandemic influenza virus in 1957 displaced 112 
the H1N1 viruses, which disappeared from human circulation. The H1N1 virus strain re-emerged in 113 
humans in 1977 and contained the same HA glycosylation sites as the H1N1 viruses circulating in 114 
the 1950s. In 1986, glycosylation site 144 was replaced by a glycosylation on position 142 (H3 115 
numbering: 128; these glycosylation sites are incompatible), and an additional glycosylation on site 116 
71 (H3 numbering: 59) was acquired almost simultaneously. In 1987 glycosylation site 172 was 117 
lost, and since then the circulating H1N1 viruses, including those circulating just prior to the 118 
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emergence of 2009 pH1N1, contained glycosylation sites 71, 142 and 177 in the globular head of 119 
HA (Fig. 2A-C ). Since the glycosylation status of the 2009 pH1N1 is the same as that of the 1918 120 
H1N1 pandemic virus, the 2009 pH1N1 virus has the potential to acquire the same or similar 121 
glycosylations over time as a result of immune selection pressure (6). We then assessed the specific 122 
effect of additional glycosylations on virulence and antigenic properties of the 2009 pH1N1 virus. 123 
 124 
Additional glycosylations in the globular head of the HA attenuate the pH1N1 virus in vivo 125 
but not in vitro. 126 
We generated 2009 pH1N1 (Neth/09 strain) recombinant viruses differing only by the sequential 127 
addition of HA glycosylations to mimic the temporal appearance of these sites in the seasonal 128 
H1N1s. Despite several attempts we were unable to rescue a virus containing the HA glycosylation 129 
sites 144, 172 and 177 in the Neth/09 background, suggesting that the combination of these specific 130 
glycosylations might require additional compensatory mutations. Nevertheless, all other mutant 131 
viruses were successfully rescued. In vitro phenotypic analyses of these recombinant viruses 132 
showed that only the virus containing 4 additional glycosylations (Neth/09 HA 71-142-172-177) 133 
had a smaller plaque phenotype in MDKCs (Fig. 3A). Addition of HA glycosylation sites resulted 134 
in slower mobility of the HA in SDS-PAGE, consistent with the use of these sites (Fig. 3B). 135 
Analysis of the HA content of each of the mutant viruses revealed that the glycosylation mutants 136 
had a decreased amount of HA incorporated into virions as compared to the rWT virus (Supp. Fig. 137 
1). When we assessed the viruses’ susceptibility to the antiviral drug oseltamivir, a neuraminidase 138 
inhibitor, we found no detectable differences amongst all the recombinant viruses utilizing the NA 139 
Star chemiluminescent substrate cleavage assay. In a tissue culture virus replication assay we 140 
observed that all viruses displayed similar sensitivity to oseltamivir (Supp. Fig. 2A and B). We 141 
performed growth kinetics to evaluate the effects of these glycosylations on the virus’ ability to 142 
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replicate in primary differentiated human tracheobroncheal epithelial cells (HTBE). All viruses 143 
replicated at high levels (>107 pfu/ml), similar to those of the original WT Neth/09 isolate virus 144 
(Fig. 3C), indicating that these additional glycosylations did not affect infection of human cells. We 145 
next evaluated the pathogenic potential of the recombinant glycosylated viruses in C57BL/6 mice. 146 
We found a glycosylation dependent attenuation of virulence in mice (i.e. the more glycosylation 147 
sites in the HA the less pathogenic), as assessed by body weight loss (Fig. 4A-E). Only the virus 148 
containing glycosylation site 144 showed weight loss patterns similar to those seen in mice infected 149 
with WT Neth/09 virus (Fig. 4B). All viruses with two or more extra glycosylation sites were 150 
severely attenuated (Fig. 4C-E). Morbidity correlated with lung viral titers in mice during the initial 151 
7 days of infection. Animals infected with the 144-172, 71-142-177 and 71-142-172-177 had 152 
substantially lower titers as compared to WT Neth/09.  153 
To determine if this is also the case in a different animal model, we assessed the virulence of the 154 
first mutant virus that demonstrated a drastic difference in morbidity in mice, the144-172 155 
glycosylated virus, as compared to the WT virus in ferrets, which is widely accepted as one of the 156 
best animal models to study pathogenesis of influenza viruses. There was a statistically significant 157 
decrease in the overall weight loss seen in the animals infected with the 144-172 virus (Fig. 4G). 158 
Interestingly, the nasal wash titers obtained from both groups through day 7, and titers of the nasal 159 
turbinates on day 3 showed no differences (Figs. 4H and I). However, the trachea and the lungs of 160 
ferrets at day 3 showed a lower virus titer for the 144-172 virus as compared to WT Neth/09 (Fig. 161 
4I). This suggests that while glycosylated H1N1 viruses can replicate to similar levels in the upper 162 
respiratory track (in the nose), they are less able to infect and replicate in the lower respiratory track 163 
(trachea and lungs). 164 
 165 
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HA glycosylation site 144 evades the polyclonal antibody response against WT HA while 166 
inducing a broader polyclonal response in mice. 167 
To gain insights into the effects of glycosylation on the antigenic properties of the H1N1 viruses, 168 
we tested the HA inhibitory (HI) activity of sera obtained from mice infected with each of the 169 
glycosylation mutant viruses against each other (Table 1). We attempted to confirm the antigenic 170 
integrity of the mutant viruses during infection by sequencing the HA and NA genes. No 171 
compensatory changes were found for virus with glycosylation 144 during the first 5 days of 172 
infection. At the dose given (1X103 pfu), no sequences were obtained at day 2 p.i. for the other 173 
glycosylated viruses, suggesting that they are cleared soon after the infection and that the humoral 174 
response observed is raised against the original inoculums . Nevertheless, we cannot rule out that 175 
compensatory mutations might still arise during this short period of infection. The WT 2009 H1N1 176 
virus is highly immunogenic (3), therefore mice infected with rWT virus had consistently higher HI 177 
titers than mice infected with any of the glycosylation mutant viruses. In order to compare the cross-178 
reactivity of sera, we used samples that had a homologous HI titer of 320-160, except for samples 179 
obtained from infection with a virus glycosylated only on site 177 that had a homologous HI titer of 180 
80 (Table 2). Infection of mice with rWT virus or the 71-142-177 or 71-142-172-177 glycosylated 181 
viruses resulted in low or no detectable sera HI activity to the glycosylated viruses 144 and 144-182 
172, while varying levels of cross-reactivity remained against the other viruses. Surprisingly, 183 
infection with viruses containing the 144 or the 144-172 glycosylations elicited antibody responses 184 
capable of cross-reacting with all of the HA glycosylation mutant viruses and the WT Neth/09 virus 185 
in the HI assay. This was also true when we tested the neutralizing activity of sera obtained from 186 
mice infected with the rWT and 144 viruses. The 144 sera neutralized both viruses at similar levels, 187 
while the rWT sera had a 4 fold lower neutralizing activity against the 144 glycosylated virus as 188 
compared to its homologous neutralizing activity (Supp. Fig 3). We speculated that glycosylation 189 
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site 142, which is only two amino acids apart from site 144, might also confer the same HI activity. 190 
Thus, to determine whether the specific effects on the breadth of neutralization seen was a distinct 191 
feature of glycosylation site 144, we generated additional viruses carrying a single glycosylation 192 
site at position 142 or 172 or 177, as well as a virus with two glycosylation sites at positions 71 and 193 
142. The viruses containing 142, 172 and 71-142 were severely attenuated in mice, similar to the 194 
viruses carrying two or more glycosylations, whereas the virus containing a glycosylation at site 195 
177 caused weight loss similar to that caused by the virus containing site 144 (Suppl. Fig 4). 196 
Remarkably, analysis of HI activity elicited by infection with these viruses showed that other single 197 
or double glycosylations, including site 142, resulted in a narrower humoral response that had no 198 
activity against viruses containing site 144 (Table 2). Taken together, this indicates that most of the 199 
polyclonal HI activity induced by the viruses is directed against one site, likely site Sa. This site 200 
seems to be efficiently masked by the 144 glycosylation and thus viruses carrying the 144 201 
glycosylation can escape the response elicited by all other glycosylation mutant viruses.  Moreover, 202 
glycosylation at position 144 changes the pattern of the polyclonal antibody response, which now 203 
appears to be against multiple antigenic regions in the HA and is not masked by a single or multiple 204 
glycosylation events. In contrast, infection with viruses containing other single glycosylations or 205 
glycosylations at positions 71-142, 71-142-177 or 71-142-172-177 induce a narrower cross-206 
reactivity pattern, suggesting that the polyclonal humoral response is slightly changed but remains 207 
focused, possibly around site Sa. 208 
 209 
HA glycosylation site 144 evades the polyclonal antibody response against pH1N1 inactivated 210 
vaccine in humans. 211 
We next tested whether the 2009 pH1N1 inactivated vaccine (study DMID 09-0047) elicited 212 
antibody responses in humans with inhibitory activity against 2009 H1N1 viruses bearing 213 
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glycosylated HAs. We found that most adult individuals that received the 2009 pH1N1 monovalent 214 
vaccine had detectable antibody responses to all the glycosylation mutant viruses (Fig. 5 and Supp. 215 
Table 1). Nonetheless, the lowest cross-reactivity was seen with viruses containing the 144 (and the 216 
144-172) glycosylation sites. Since the level of previous exposure to influenza virus in humans 217 
could impact their polyclonal antibody responses, we also assessed the sera HI titers in a more naïve 218 
population (children <18 years of age) that were immunized with the monovalent p2009 H1N1 219 
inactivated vaccine. The sera activity of pediatric individuals also had a similar cross-reactivity 220 
pattern to the ones of adults, showing lower HI activity against the 144 and the 144-172 221 
glycosylation mutant viruses compared to WT, 71-142-177 or 71-142-172-177 glycosylated viruses 222 
(Supp. Table 1). Overall, 10 to 13 individuals showed undetectable increases in HI activity levels 223 
when tested against the 144 and the 144-172 viruses (versus only 2 individuals when the other 224 
viruses were used, including the WT). When we analyzed the distribution of the increase in HI 225 
activity against each glycosylation mutant virus, we found that there was a significantly lower 226 
median of the distribution for viruses 144 and 144-172 but not for viruses 71-142-177 and 71-142-227 
172-177 (Fig. 5). This is in close agreement with the mouse serology results, emphasizing the 228 
masking effects of glycosylation at site 144. As expected, the trivalent seasonal vaccine of 2009 229 
containing a previously circulating seasonal H1N1 virus, did not induce significant HI titers against 230 
pH1N1 viruses, independently of their level of glycosylation (Supp. Table1). 231 
 232 
Glycosylation deletions in a recent seasonal H1N1 virus increase its in vivo virulence and elicit 233 
cross-protection against pH1N1 2009 virus challenge. 234 
To further elucidate the role of HA glycosylations in the pathogenic and antigenic properties of 235 
H1N1 viruses, we generated a set of recombinant A/PR8/34 7:1 Tx/91 HA (rWT Tx/91) 236 
glycosylation deletion viruses. The contemporary Tx/91 seasonal strain contains three extra 237 
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glycosylation sites, on sites 71, 142 and 177. Elimination of HA glycosylation sites resulted in 238 
faster HA mobility in SDS-PAGE, as expected (Fig. 6A). Infection with a sublethal dose of rWT 239 
Tx/91 virus (at 1X103 pfu) did not result in morbidity in mice. However, infection with viruses 240 
containing deletions of 2 or 3 glycosylations (rTx/91 ∆71-177 and rTx/91 ∆71-142-177) resulted in 241 
a significant level of weight loss as compared to the rWT Tx/91 virus (Fig. 6B). The highest 242 
morbidity was observed in the ∆71-142-177 virus, a virus that resembles the 2009 pH1N1 in that it 243 
has no glycosylation sites in the globular head of HA. This again confirms that glycosylations of 244 
HA negatively affect the in vivo pathogenic potential of human H1N1 viruses. To investigate if 245 
infection with these glycosylation deletion viruses can elicit cross-protective humoral responses to 246 
the antigenically highly distant WT 2009 H1N1 virus, we challenged these animals on day 27 p.i. 247 
with 100 times the 50% lethal dose (LD50) of WT Neth/09 virus. The mice previously infected with 248 
rWT Tx/91 all succumbed to the Neth/09 challenge, and the mice infected with the virus containing 249 
a single deleted glycosylation on site 71 (∆71) showed substantial weight loss and only a 20% 250 
survival rate (Fig. 6C). In contrast, although the animals infected with viruses with glycosylation 251 
deletions on sites 71-177 (∆71-177) and 71-142-177 (∆71-142-177) showed a substantial loss in 252 
body weight (up to ~20%) they all survived the lethal challenge with Neth/09, with animals infected 253 
with ∆71-142-177 showing an overall lower morbidity level (Fig. 6C). We sequenced lung 254 
homogenates at 2 and 5 days p.i. to evaluate if additional adaptive or compensatory mutations 255 
emerged during infection in mice. No sequence changes were detected in the homogenates 256 
analyzed, indicating that removal of the HA glycosylations in these viruses was responsible for the 257 
increased pathogenicity and cross-reactive humoral response observed. Since the introduced amino 258 
acid substitutions (N71K, S73N, T144D and N177K) not only deleted the glycosylations sites at 259 
positions 71, 142 and 177 but also made the Tx/91 antigenic site Sa resemble that of Neth/09, we 260 
generated a second set of mutant viruses containing the non-related amino acid substitutions N71Q, 261 
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N142Q and N177Q, respectively. Mice infected with the viruses with two or three glycosylation 262 
deletions also showed an increased weight loss (Suppl. Fig 5) and when challenged 29 days p.i. they 263 
also had an enhanced protection against a lethal challenge with 100 LD50 of WT Neth/09 (fig. 6D). 264 
These data show that HA glycosylations play an important role in masking antigenic sites and in 265 
eliciting protective immune responses against antigenically diverse H1N1 influenza virus strains. 266 
267 
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Discussion 268 
In this study we have evaluated the effect of glycosylations in the HA protein on virulence and 269 
antigenic cross-reactivity in the context of the current 2009 pH1N1 strain. Utilizing a set of 270 
recombinant 2009 pH1N1 viruses engineered to mimic the temporal acquisition of glycosylations in 271 
the HA protein as those observed for the historical seasonal H1N1 viruses, we demonstrate that 272 
glycosylations play an important role in modulating the pathogenesis and the antigenic properties of 273 
these viruses. 274 
 275 
Initial sequence analysis of the 2009 pH1N1 virus revealed a drastic difference as compared to the 276 
seasonal H1N1 viruses (Bris/59-like) that were circulating worldwide at the time of the outbreak 277 
(18-20). Close analysis of the HA protein, and experimental studies from us and others (3-6), 278 
showed that the 2009 pandemic virus was more closely related to older H1N1 viruses that circulated 279 
in humans before the 1950’s. The HA of the H1N1 seasonal viruses has acquired glycosylation sites 280 
during its evolution in humans, likely as a result of immune selection pressure. Of interest, a 281 
number of glycosylations have emerged but eventually disappeared and some became fixed in time 282 
(Fig. 1)(9). This suggests that during viral evolution, some of these glycosylations can be 283 
deleterious for the virus, while others might provide fitness and/or an immune escape advantages 284 
resulting in the emergence of drift variants in humans. Because the 2009 pH1N1 and the 1918 285 
H1N1 pandemic viruses have the same glycosylation pattern in HA1, there is a possibility that with 286 
time the 2009 pH1N1 strain might undergo a similar evolutionary pattern and might acquire similar 287 
glycosylations in the HA as observed previously with the seasonal H1N1 (Fig. 1 and 2). We 288 
therefore engineered 2009 pH1N1 viruses with additional glycosylation motifs that occurred 289 
naturally in human H1N1 viruses since their emergence in 1918. This also allowed us to investigate 290 
 15
the potential significance of such mutations in the context of protective antibody responses elicited 291 
by the 2009 pH1N1 vaccine in humans. 292 
 293 
The recombinant Neth/09 viruses containing additional glycosylation sites in the HA were 294 
attenuated in mice and ferrets (Fig. 4). This could be partly due to the reduced amount of the mutant 295 
HAs incorporated into virions as compared to WT (Supp. Fig. 1). Nonetheless, the infection and 296 
replication capacity of the glycosylated viruses in MDCK and primary HTBE cells were not 297 
significantly affected (Fig. 3), including when assessing their susceptibility against antiviral drug 298 
oseltamivir (Supp. Fig. 2). These results are consistent with studies demonstrating that glycosylated 299 
viruses are more sensitive to the innate immune activity of collectins present in lung fluid, but 300 
replicate equally well in mouse airway macrophages or MDCK cells in vitro (13, 14, 21-23). 301 
However, this sensitivity to collectins appears to be dependent on the number and position of the 302 
glycosylations added onto the HA (22). Indeed, our results in mice infected with single 303 
glycosylations showed attenuation for some of the mutants (e.g. 142 and 172), but not for others 304 
(e.g. 177), suggesting that the selection of glycosylations in human influenza viruses is modulated 305 
by both pre-existing immunity (antibodies) and the activity of collectins. Nonetheless, here we have 306 
not tested the neutralizing activity of collectins found in the lung fluid of humans. Therefore it is 307 
currently unclear whether influenza virus pathogenesis in humans is also regulated in similar 308 
manner and to the same extent by collectins and thus this warrants further investigation. Moreover, 309 
glycosylations can also result in decreased binding to the viral receptor (lower avidity), becoming 310 
attenuated due to compromised viral fitness (15). When we infected naïve ferrets with the WT and 311 
the 144-172 viruses, we observed differences in viral load in the lungs and trachea of the 144-172 312 
infected animals, but not in the nasal turbinates. Infection in these animal model with glycosylated 313 
pH1N1 viruses is largely reminiscent of infection with H1N1 seasonal viruses, which generally do 314 
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not produce disease in mouse models (24, 25) and in ferrets replicate to high titers in the upper 315 
respiratory tract but not in the lower respiratory tract (26, 27). Of interest, not only was virulence 316 
decreased by adding the naturally occurring glycosylation sites in the pH1N1 viruses, but also 317 
virulence was increased by deleting these glycosylations in the HA of the Tx/91 seasonal H1N1 318 
virus. Therefore acquisition of glycosylations in the HA seems to reduce the virulence of the human 319 
H1N1 viruses due to multiple mechanisms (15, 22, 23). Interestingly, the lack of these 320 
oligosaccharides in the globular head of the HA is a feature shared with the old seasonal H1N1, the 321 
classical swine influenza viruses and the current 2009 pH1N1 strains, which display increased 322 
virulence in mice (4, 5, 25). One caveat of this study is that we have not tested the effect of these 323 
glycosylation in the background of other human influenza H1N1 viruses, which might have 324 
additional compensatory mutations as they circulate in humans. In fact, we were unable to rescue a 325 
virus containing HA glycosylation sites 144, 172 and 177 in the Neth/09 background, indicating 326 
that specific HA structures might or not allow the deletion or introduction of certain glycosylations 327 
or combinations of them. Additional studies utilizing HA from diverse H1N1 strains would aid our 328 
understanding of the role glycosylations in the evolution of influenza virus in humans. 329 
 330 
Antigenic characterization of the Neth/09 glycosylation mutant viruses suggested that site Sa in the 331 
HA is a dominant antigenic region for mice and humans, since adding 1 or 2 glycosylation on 332 
residues around this site (e.g. sites 144 and 144-172) was sufficient to significantly reduce the HI 333 
activity of the polyclonal response elicited by the WT unglycosylated virus. Of these two sites, 144 334 
seems to be the one responsible for this effect, as a dramatic reduction in HI was not seen in the 71-335 
142-172-177 virus or viruses carrying single glycosylations at 142, 172, or 177.  We speculate that 336 
glycosylation at 144 covers a different area than glycosylations at positions 142, 172 and 177 (Fig. 337 
2B and C), or it might be placed in a different orientation, thus making it unique in its ability to 338 
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modulate the antigenic effects of HA. In agreement, immunization of human adults with the current 339 
inactivated 2009 pH1N1 vaccine strain induced an overall polyclonal antibody response reminiscent 340 
of the one in pH1N1 infected mice (Table 1, Fig. 5 and Supp. Table 1), as glycosylation at site 144 341 
was the most efficient in escaping HI reactivity. Similarly, the pediatric post-vaccination sera 342 
analyzed showed considerable activity against the 71-142-177 and the 71-142-172-177 viruses, but 343 
less against the 144 and144-172 viruses (Fig. 5 and Supp. Table 1). Overall this indicates that 344 
glycosylation of human H1N1 viruses greatly affects their antigenic properties. Of note however, in 345 
our study we only analyzed glycosylations that have previously appeared in human H1N1 viruses. 346 
Nonetheless, it is possible that as a consequence of immune mediated antigenic pressure, new 347 
changes in HA will occur and drive the appearance of new glycosylation sites in the 2009 pH1N1 348 
strain modulating its antigenic properties as it continues to circulate seasonally worldwide. If this is 349 
the case, the impact of such glycosylations in virulence and antigenicity will have to be further 350 
investigated. 351 
 352 
Importantly, infection with viruses harboring glycosylation sites 144 and 144-172 induced a broader 353 
polyclonal response capable of cross-reacting with all the WT and Neth/09 glycosylated viruses 354 
generated (Tables 1 and 2). The increased breadth of the polyclonal response is likely due to 355 
shielding of the immunodominant site Sa, causing a change of the antigenic focus that redirects the 356 
humoral response to other epitopes. This is in agreement with a recent study demonstrating that 357 
over time changes in the globular head of HA are focused on antigenic regions that are unmasked 358 
by changes in glycosylations (9). It should be noted that here we have analyzed sera from mice 359 
infected with the 144 and 144-172 viruses and thus, whether these viruses in humans could also 360 
induce a similar broad polyclonal response can only be speculated. Remarkably, the cross-361 
protection against the WT Neth/09 virus observed in the mice infected with a sub-lethal dose of the 362 
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Tx/91 deletion mutants ∆71-177 and ∆71-142-177 emphasizes the importance of glycosylations in 363 
“distracting” or redirecting the humoral response. These results also point to the crucial 364 
evolutionary role of the appearance of glycosylations around site Sa, since deleting glycosylations 365 
within or close to this region has a profound effect on cross-reactivity. Altogether, these findings 366 
highlight the immune-modulatory effects of specific glycosylations in the antigenic properties of 367 
HA, and also provide a powerful rationale to investigate the effects of glycosylations on the breadth 368 
of immune responses to infection and vaccination. 369 
370 
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Materials and Methods 371 
Human specimens. 372 
The studies involving the use of human serum specimens (Clinical Trial DMID 09-0047) were 373 
reviewed and approved by the Institutional Review Boards of both the Saint Louis University 374 
School of Medicine and of Icahn School of Medicine at Mount Sinai School. We utilized pre- and 375 
post-vaccination sera obtained from subjects who were 18 years of age or older (adults) and from 376 
individuals ages 1 to 17 (pediatric), that were enrolled in clinical trials to assess the safety and 377 
immunogenicity of an inactivated 2009 pH1N1 influenza vaccine based on strain 378 
A/California/07/2009 performed at the National Institute of Allergy and Infectious Disease Vaccine 379 
and Treatment Evaluation Unit at Saint Louis University. The sample size of our study was 52 pairs 380 
of pre- and post-vaccination sera. Samples were selected randomly upon availability of pre- and 381 
post sera, to cover age ranges for pediatric (1 to 17 years of age, n=14) and adult (18 to 74 years of 382 
age, n=36), and vaccination status (i.e. individuals that had received at least 1 dose of the 2009 383 
pH1N1 influenza vaccine). As controls we also used pre- and post-vaccination sera from 2 adults 384 
that were immunized with the seasonal 2009 TIV, but that did not received the 2009 pH1N1 (Table 385 
S1). These samples were obtained under approved protocols where informed consent was obtained 386 
after the nature and possible consequences of the studies were explained. Samples used were 387 
deidentified of any patient information. The experiments conducted to assess the reactivity of these 388 
human sera against seasonal H3N2, H1N1, 2009 H1N1 and the glycosylation mutant HAs were 389 
performed blinded in duplicate. 390 
 391 
H1N1 HA virus sequences and alignment. 392 
The HA sequence from all the H1N1 human viruses available through the Influenza Research 393 
Database and the Influenza Virus Resource Database were downloaded and aligned utilizing 394 
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ClustalW and edited manually with the BioEdit Sequence Alignment Editor software. HA1 395 
sequences containing representative glycosylation patterns based on at least two original isolates per 396 
year were selected for further analysis. Years not represented correspond to either a lack of an 397 
isolate sequence for that year or an unclear prototype sequence due to few sequences available. The 398 
GenBank accession numbers of the HAs depicted in Fig. 1 are: AF117241.1, CY034132, 399 
AF389118, CY009324, CY020445, CY013271, CY009276, CY020285, CY021709, CY009596, 400 
CY009612, CY019947, CY019971, CY009332, CY021821, AB043482, CY077748, CY077725, 401 
CY009340, CY021053, L19023, DQ508897, CY011296, CY021909, CY020181, CY021029, 402 
CY010364, Z54286, CY036823, L20111, CY020437, CY021725, DQ508873, CY019779, 403 
CY033655, CY012872, CY017011, DQ415317, EU103824, CY025026, CY010332, CY006675, 404 
CY019883, U53162, CY007467, CY016675, CY027875, AF386775, CY058487.1, CY040114, 405 
FJ984355, GQ150342, GQ149654, GQ117044, FJ966974, CY039527.2. The glycosylation sites 406 
were predicted by the motif N-X-S/T. 407 
 408 
Cell lines and Viruses. 409 
Human embryonic kidney (293T) cells were maintained in DMEM supplemented with 10% FBS 410 
and 1000 U/ml penicillin/streptomycin. Madin–Darby canine kidney (MDCK) cells were 411 
maintained in MEM supplemented with 10% FBS and penicillin/streptomycin. Reagents for cell 412 
culture were purchased from Gibco Life Technologies. The virus strains A/Texas/36/1991 H1N1 413 
(Tx/91), A/Brisbane/59/2007 H1N1 (Bris/59) and A/Brisbane/10/2007 H3N2 (Bris/10) were grown 414 
in 10-day-old embryonated eggs. The A/California/04/2009 (Cal/09) and A/Netherlands/602/2009 415 
(Neth/09) isolates and all recombinant virus stocks were grown in MDCK cells. 416 
 417 
Generation of recombinant viruses. 418 
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a. A/Netherlands/602/2009 isolate rescue plasmids. Sequence analysis showed that segments 419 
encoding the PB2, PB1, M and NS proteins were identical between the A/California/04/2009 and 420 
A/Netherlands/602/2009 isolates. We thus used the plasmids pDZ-PB2, -PB1, -M and -NS of strain 421 
A/California/04/2009 described previously (28, 29). We cloned the remaining segments by isolating 422 
viral RNA from supernatants obtained from MDCK cells infected with the A/Netherlands/602/2009 423 
virus isolate using the QIAamp viral RNA mini kit (Qiagen) and used segment-specific primers 424 
containing the SapI restriction sites to clone NP, HA and NA into the pPolI plasmid as previously 425 
described (29). For PA, we performed site-directed mutagenesis using the A/California/04/2009 426 
pPolI-PA plasmid as template and mutated 3 nt to obtain the WT Neth/09 PA gene. Next, segments 427 
PA and NP were sub-cloned from vector pPolI into the bidirectional vector pDZ using SapI 428 
restriction sites. Constructs encoding the glycosylation mutants were generated by site-directed 429 
mutagenesis of the WT Neth/09 pPol-HA using the Quick Change Site-Directed Mutagenesis Kit 430 
(Stratagene). The amino acid changes made in each case to add glycosylation sites were as follows: 431 
K71N and N73S for site 71, D144T for site 142, D144N and N146T for site 144, G172N for site 432 
172, and K177N for site 177. 433 
 b. Rescue of WT A/Netherlands/602/2009 and respective glycosylation mutant viruses. The 434 
Neth/09 based recombinant influenza A viruses were generated by transfecting 293T cells with 0.5 435 
g of each of ten plasmids utilizing Lipofectamine 2000 (Invitrogen) according to the 436 
manufacturer’s instructions. The plasmid mixture contained the six pDZ vectors encoding the PB2, 437 
PB1, PA, NP, M and NS genes and two pPolI vectors encoding the HA and NA genes. We included 438 
the A/WSN/33 expression plasmids pCAGGS-HA and pCAGGS-NA to enhance rescue efficiency. 439 
At 16-20 hr post-transfection, MDCK cells were added onto the 293T cells and medium was 440 
changed to DMEM with penicillin/streptomycin, 0.3% bovine albumin and 1ug/ml TPCK-treated 441 
trypsin (Sigma-Aldrich, St. Louis, MO). Supernatants were harvested 24-36 hr post addition of the 442 
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MDCK cells. The rescued viruses were plaque purified and re-grown in MDCK cells for 48 hrs to 443 
make passage 1 stocks, which were used for all experiments shown. Titers of virus stocks were 444 
determined in triplicate by plaque assay on MDCK cells. The sequence of each recombinant virus 445 
was confirmed by sequencing the entire genome. 446 
c. Generation and rescue of A/PR8/34 7:1 Tx/91 HA glycosylation deletion viruses. We performed 447 
fusion PCR to generate pDZ-HA plasmids containing glycosylation mutants of the Tx/91 HA to 448 
delete 1, 2 or 3 glycosylation sites located in the globular head of this contemporary seasonal H1N1 449 
HA. The following amino acid changes were made to delete each glycosylation site to match the 450 
residues found in the Neth/09 isolate: N71K and S73N to delete site 71, T144D to delete site 142, 451 
and N177K to delete site 177.  A second set of glycosylation deletion mutants was generated to 452 
contain the non-related amino acids N71Q to delete site 71, N142Q to delete site 142 and N177Q to 453 
delete site 177. We utilized the remaining 7 genes of A/PR8/34 (PR/34) cloned into the pDZ 454 
plasmid to rescue PR/34 7:1 TX/91 HA wild type and mutant recombinant viruses as described 455 
above.  456 
 457 
Plaque phenotype and in vitro virus growth analysis. The plaque size phenotype was evaluated 458 
by performing a plaque assay after infecting MDCK cells with ~100 pfu of each recombinant virus 459 
as shown. At 48 hr p.i. the cells were fixed with 4% formaldehyde and plaques were visualized by 460 
immunostaining with the mouse monoclonal antibody E10 that recognizes the amino-terminal 461 
peptide common to the M1 and M2 proteins. Growth curves were performed in differentiated 462 
primary human tracheobronchial epithelial (HTBE) cells (Lonza). Approximately 1X105 HTBE 463 
cells were seeded onto collagen-coated 12-mm permeable membrane transwell inserts (0.4 m) in a 464 
12 well plate (Corning). The cells were grown submerged in BEGM Bronchial Epithelial Cell 465 
Growth Medium (Lonza) for 4 days until confluence was achieved and then differentiation was 466 
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established by removing the media from the apical surface and further culturing the cells for 4 467 
weeks in this air-liquid interface. During this time the media on the basolateral side was replaced 468 
every 2 days. Prior to virus infection the cell monolayers were washed thoroughly with PBS to 469 
remove the mucus accumulating on the apical surface of the cells. Triplicate wells were inoculated 470 
with each virus shown at a multiplicity of infection (MOI) of 0.001 pfu/cell. Virus was collected at 471 
the indicated time points by adding 100 l of PBS to each well for 30 mins at 37C. Viral titers were 472 
determined by standard plaque assay using MDCK cells. 473 
 474 
Western blot assays. 475 
MDCK cells infected at an MOI of 5 for 12 h with the indicated viruses were lysed in NP-40 lysis 476 
buffer (50 nM Tris, 150 nM NaCl, 5 mM EDTA, 30 mM NaF, 40 mM -glycerophosphate, 10 % 477 
glycerol and 0.25% NP-40) containing Complete Mini protease inhibitor (Roche). Clarified lysates 478 
were boiled for 5 min and proteins were separated on a NuPAGE 4-12% Bis-Tris gradient gel 479 
(Invitrogen) under non-reducing conditions for the WT and mutant Neth/09 viruses, or under 480 
reducing conditions for the Tx/91 WT and the respective glycosylation deletion mutant viruses. 481 
Western blots were performed to detect proteins transferred to PVDF membranes, by incubation 482 
with the rabbit polyclonal antiserum 3951 raised against a PR8 virus lacking H1, which had been 483 
removed by acid and DTT treatment (30). 484 
 485 
Mouse experiments 486 
For mouse experiments groups of five mice were used to determine weight loss and survival. Unless 487 
stated otherwise groups of three mice were used to determine lung virus titers.  488 
a. Infections, body weight loss and survival. All mouse experiments were carried out in strict 489 
accordance with institutional Animal Care and Use Committee (IACUC) guidelines, and have been 490 
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approved by the IACUC of Icahn School of Medicine at Mount Sinai. 7 to 9-week-old C57BL/6 491 
female mice (Jackson Laboratories) were anesthetized by intraperitoneal injection of ketamine-492 
xylaxine before intranasal infection with the indicated virus at doses of the virus diluted in 50 l of 493 
PBS. Body weight and survival were monitored daily for 14 days. Mice showing more than 25% of 494 
body weight loss were considered to have reached the experimental end point and were humanely 495 
euthanized. 496 
b. Lung viral titers and sequencing. Lungs of infected mice were excised aseptically on the 497 
indicated days post-infection and stored at -80°C until further processing.  For virus titrations the 498 
tissues were homogenized in 1ml of PBS using a mechanical homogenizer (MP Biochemicals). The 499 
viral titers in the clarified supernatant homogenates were quantified by standard plaque assay on 500 
MDCK cells. To determine the presence of compensatory mutations during infection, viral RNA 501 
was also extracted from the homogenate using the QIAamp Viral RNA Mini Kit (Qiagen) following 502 
the manufacturer’s instructions. The HA and NA genes corresponding to each mouse at the different 503 
time points were amplified and sequenced by standard methods. 504 
c. Neth/09 challenge. 8-week old mice were infected with the indicated rTx/91 viruses.  Mice were 505 
allowed to seroconvert for 27 days at which time they were challenged with 100 times the 50% 506 
lethal dose (LD50%) of A/Netherlands/602/2009. Survival and body weight loss were monitored for 507 
13 days p.i. 508 
 509 
Ferret experiments. 510 
Animal research was conducted under the guidance of the Centers for Disease Control and 511 
Prevention's IACUC in an Association for Assessment and Accreditation of Laboratory Animal 512 
Care International-accredited animal facility. 513 
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a. Infections, body weight loss and nasal wash titers. We used 8 to 12 months old male Fitch 514 
ferrets, (Triple F Farms) that were serologically negative by hemagglutination inhibition for 515 
currently circulating seasonal H3N2, the previously circulating seasonal H1N1 and the pandemic 516 
2009 H1N1 influenza A viruses, to assess the virulence of the indicated viruses. Three ferrets per 517 
group were anesthetized with an intramuscular injection of a ketamine hydrochloride (24 mg/kg)-518 
xylazine (2 mg/kg)-atropine (0.05 mg/kg) cocktail and were infected intranasally with either the WT 519 
Neth/09 HA or the HA 144-172 glycosylation mutant virus at 106 pfu in a final volume of 1 ml of 520 
PBS. Body weights were measured daily for 12 days and are represented as the percentage weight 521 
compared to the initial weight. The nasal cavities of the ferrets were washed with 1 ml of PBS on 522 
days 1, 3, 5 and 7 p.i.. The viral titers of the nasal washes were determined by standard plaque assay 523 
on MDCK cells. 524 
b. Tissue viral titers.  Three ferrets per indicated group were infected with 106 pfu of each virus as 525 
described above. On day 3 p.i. the ferrets were euthanized and the lungs, trachea and nasal 526 
turbinates were aseptically collected. The tissue specimens were immediately frozen on dry ice and 527 
stored at –70°C until processed. Frozen tissue specimens were thawed, weighed, and then 528 
homogenized in cold PBS using disposable sterile tissue grinders (Kendall). Tissue homogenates 529 
were clarified and virus titers in the clear supernatants were determined by standard plaque assay on 530 
MDCK cells. 531 
 532 
Hemagglutination inhibition (HI) assay of mouse and human sera. 533 
Mouse sera were obtained from animals infected with the indicated viruses on day 28 p.i. HI assays 534 
were performed with sera pooled from 3 infected animals per virus that were selected to contain at 535 
least 160 HI units against the homologous virus, except for the virus containing glycosylation on 536 
site 177 that only elicited HI titers of 80. The HI assays were conducted essentially as previously 537 
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described (3, 31). Briefly, we used trypsin-heat-periodate treatment to inactivate the mouse, ferret 538 
and human sera by mixing a half volume of trypsin 8 mg/ml (Sigma-Aldrich) in 0.1 M phosphate 539 
buffer, pH 8.2, with one volume of serum and the samples were incubated for 30 min at 56°C. The 540 
samples were cooled to RT, mixed with three volumes of 0.11 M metapotassium periodate and 541 
further incubated at RT for 15 min. The samples were then mixed with three volumes of 1 % 542 
glycerol saline and incubated for 15 min at RT. The samples were finally mixed and incubated with 543 
2.5 volumes of 85 % saline to dilute the samples to a concentration of 1:10. We performed HI 544 
assays of sera following standard protocols (32). Briefly, two-fold serial dilutions of mouse or 545 
human sera were mixed and pre-incubated in 96-well plates with 8 HA units of virus per well for 30 546 
min at 4°C. Turkey (for Bris/10 and Neth/09) or chicken (for Bris/59) red blood cells were added at 547 
a final concentration of 0.25 %, and the plates were incubated at 4°C for 30 min. HI titers were 548 
determined as the reciprocal of the highest dilution that displayed haemagglutinating activity. 549 
 550 
Statistical analysis. 551 
For mouse studies we assessed statistical significant differences (P < 0.05) in body weight loss in 552 
groups of five mice (n=5) using a two-tailed unpaired Student’ s t –test, and for establishing 553 
statistical differences for survival curves we utilized the log-rank test. For the ferret experiments 554 
statistical significance (P < 0.05) of the weight loss over time was performed by analysis of the area 555 
under the curve (AUC), interpreted as the total weight loss of the animal group (n=3) as a function 556 
of time, using the Wilcoxon-matched pairs test. For the human sera (n=52) statistical significance 557 
was tested using the Wilcoxon rank sum test on the distributions. 558 
559 
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FIGURE LEGENDS 710 
Fig. 1. Acquisition of glycosylation sites in HA of human H1N1 subtype over time prior to the 711 
emergence of the 2009 H1N1 virus.  Amino acid alignment of antigenic sites in the HA1 of 712 
seasonal H1N1 strains circulating in humans since 1918 until just prior to the emergence of the 713 
2009 H1N1 pandemic virus. Four representative 2009 H1N1 pandemic isolates are also included as 714 
reference. Alignment shows selected prototypical reference strains. Colored shading (purple, yellow 715 
and green) depicts known antigenic sites listed on top. Yellow boxes represent conserved 716 
glycosylations and red boxes represent glycosylations that appear and disappear over time. Arrows 717 
on the right show the year glycosylations appeared at the indicated residue positions. 718 
 719 
Fig. 2. Modeling of H1N1 glycosylations over time. (A) Time line illustrating the year of 720 
acquisition of glycosylations in the globular head of the HA protein. Numbers in red indicate the 721 
amino acid position of the glycosylation site that are conserved amongst human H1N1 isolates since 722 
their emergence in 1918, and numbers in black indicate the amino acid position of the glycosylation 723 
sites that appeared in the specific years shown at the bottom. Arrows denote the persistence of 724 
glycosylation sites through time, and circles represent their disappearance. Discontinuous lines 725 
indicate the time period from 157 to 177 when H1N1 viruses did not circulate in humans. (B) 726 
Representation of an HA monomer with the antigenic sites highlighted in red and the glycosylation 727 
sites in yellow. The stem region of HA is denoted in silver. Amino acid positions refer to the H1 728 
nomenclature (sites 71, 142, 144, 172 and 177 correspond to H3 numbering 58, 128, 130, 158 and 729 
163, respectively). Numbers in red indicate conserved glycosylation sites. (C) Structural modeling 730 
of the trimeric HA with glycosylations as they appeared over time from 1918 to the emergence of 731 
the 2009 pH1N1 virus. The glycan structures for the sites shown in yellow have been modeled onto 732 
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the Cal/09 HA (PDB 3LZG) and are also depicted in yellow. All models were made with 733 
MacPyMol. 734 
  735 
Fig. 3. Phenotypic characterization of HA glycosylation mutant 2009 pH1N1 viruses. (A) 736 
Plaque morphology of rescued A/Netherlands/602/2009 HA glycosylation mutant viruses in MDCK 737 
cells. (B) Western blot analysis of whole cell lysates obtained from MDCK cells infected at an MOI 738 
of 5 for 12 h. Lysates were run under non-reducing conditions and blots were detected with rabbit 739 
polyclonal antiserum 3951 raised against a PR8 virus lacking H1, which had been removed by acid 740 
and DTT treatment. (C) Growth kinetics of rescued viruses in differentiated human tracheobrochial 741 
epithelial cells infected at an MOI of 0.001. Data are shown as the average of virus titrations 742 
conducted in triplicates for each time point shown by standard plaques assay in MDCK cells. The 743 
error bars represent the +/- SD at each time point. 744 
 745 
Fig. 4. 2009 pH1N1 viruses with additional glycosylations in the HA are attenuated in mice 746 
and ferrets. (A – E) Infection of 9-week-old female C57B/6 mice with Neth/09 glycosylation 747 
mutant viruses. Groups of 5 mice per recombinant virus were infected i.n. with the indicated doses. 748 
Body weight represents the average of each group and the error bars indicate the +/- SD at each 749 
time point. (F) Viral titer in the lungs of mice infected with 1X103 pfu of each mutant virus were 750 
obtained on days 2 (circle), 5 (square), and 7 (triangle) p.i. as shown. Black bars represent the 751 
average viral titer for 2 (arrows) or 3 mice per group at each time point as compared to the rNeth/09 752 
WT virus. N.D. = Not detected. (G) Body weight changes in ferrets infected (n=3 per group) with 753 
the indicated viruses. Weights are shown as the average and the error bars represent the +/_SD. at 754 
each time point. Statistically significant difference (*) of the overall body weight of ferrets during 755 
the infection period was estimated with the Wilcoxon-matched pairs test. (H) Viral titers in nasal 756 
 33
washes obtained every other day from ferrets shown in (G). (I) Viral load in tissues from ferrets 757 
(n=3) at day 3 p.i. with the indicated viruses. Values are represented as in (F). 758 
 759 
Fig. 5. HI activity of human sera after vaccination against pandemic 2009 H1N1. Pre- and post-760 
vaccination sera samples obtained from 52 subjects enrolled in clinical trials to test the safety and 761 
immunogenicity of an inactivated 2009 H1N1 influenza vaccine, were tested for their HI activity 762 
against WT Neth/09 and the glycosylation mutant viruses. For each subject the difference in HI 763 
activity between post- and pre-vaccination (HI titer post-vaccination – HI titer pre-vaccination in 764 
number of wells) was determined to normalize for pre-existing HI activity. For each virus the 765 
distribution of increase in HI activity post vaccination is plotted. The median of the distribution is 766 
marked with a red line and statistically significant differences were determined with the Wilcoxon 767 
rank sum test. 768 
 769 
Fig. 6. Deletion of glycosylation sites in the HA of Tx/91 increases virulence in mice and cross-770 
protects against the 2009 pH1N1 strain. Phenotypic characterization of recombinant influenza A 771 
viruses carrying either the wild type or glycosylation deletion mutant A/Texas/36/1991 HAs (N71K 772 
+ S73N, T144D, N177K) and the remainder 7 genes from PR8 (viruses are 7:1 rPR8 expressing 773 
Tx/91 HA). (A) Western blot analysis of lysates obtained from MDCK cells infected at an MOI of 5 774 
for 12 h with the respective glycosylation deletion mutant viruses. Lysates were run under reducing 775 
conditions and blots were detected with the polyclonal 3951 antibody. (B) 8-week-old female 776 
C57B/6 mice infected with 1X104 pfu of each virus shown. Average body weight of mice n=5 per 777 
group. Error bars denote the +/- SD for each time point. (C) Mice infected in panel B were allowed 778 
to seroconvert for 27 days at which time they were challenged with 100 LD50 of Neth/09. Percent 779 
survival is shown. (D) Mice infected with 1X104 pfu of each glycosylation deletion mutant, in 780 
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which the same glycosylation sites were removed by an alternative set of amino acid substitutions to 781 
those used in B and C. At 29 days p.i. mice were challenged with 100 LD50 of Neth/09. Percent 782 
survival after challenge is shown. The student’s t-test was used to determine significance of body 783 
weight loss and the log-rank test was used to assess significance (* P<0.05) of survival outcome. 784 
 785 
Table 1. HI titers of mouse sera after infection with 2009 pH1N1 HA glycosylation mutant 786 
viruses. 787 
 Seraa 
Virusb, c rWT 144 144-172 71-142-177 71-142-172-177 
rWT 320 320 160 40 20 
144 10 160 80 <10 <10 
144-172 20 80 160 <10 40 
71-142-177 80 160 160 160 160 
71-142-172-177 160 160 320 160 160 
 788 
a Mice were infected with the recombinant Neth/09 virus containing HA glycosylations at the 789 
indicated residues. 790 
b HI titers represent the reciprocal of the highest dilution that displayed hemagglutination inhibitory 791 
activity. 792 
c Homologous titers are in bold. 793 
794 
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Table 2. HI titers of mouse sera after infection with 2009 pH1N1 HA single and double 795 
glycosylation mutant viruses. 796 
 Seraa 
Virusb, c 142 172 177 71-142 
rWT 80 80 80 80 
144 <10 <10 <10 <10 
144-172 <10 10 <10 <10 
71-142-177 160 40 80 320 
71-142-172-177 80 160 40 80 
142 160 160 160 160 
172 160 320 320 160 
177 80 80 80 80 
71-142 80 40 80 320 
 797 
a Mice were infected with the recombinant Neth/09 virus containing HA glycosylations at the  798 
indicated residues. 799 
b HI titers represent the reciprocal of the highest dilution that displayed hemagglutination inhibitory 800 
activity. 801 
c Homologous titers are in bold. 802 
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 1 
SUPPLEMENTARY MATERIAL 1 
Material and Methods 2 
Analysis of the amount of HA incorporated into virions. 3 
Wildtype and glycosylation mutant viruses in the background of strain A/Netherlands/602/2009 4 
were grown in MDCK cells in the presence of TPCK-trypsin. The supernatants were harvested, 5 
cleared by low-speed centrifugation and loaded onto 20% sucrose cushions for ultracentrifugation. 6 
The resulting virus pellets were resuspended in PBS and subjected to PNGaseF (New England 7 
Biolabs) treatment according to the manufacturer’s protocol.  The deglycosylated virus preparations 8 
were analysed by SDS-Page and Coomassie staining of the gel. The intensities of the HA1 and NP 9 
bands were quantified by Multigauge software and plotted as ratio of HA/NP. 10 
 11 
Oseltamivir resistance tests. 12 
a. NA star assay.Viruses were grown in MDCK cells, supernatants were harvested and cleared by 13 
low-speed centrifugation. The NA star assay (Invitrogen) was performed using 1:10 dilutions of the 14 
virus-containing supernatants according to the manufacturer’s instructions. 15 
b. Inhibition of virus replication in tissue culture. MDCK were infected with the different viruses 16 
at an MOI of 0.1 in the presence of different concentrations of Oseltamivir (0/10/100 nM). 17 
Supernatants containing virus were harvested at 24h post infection and virus titers were determined 18 
on MDCK cells.  19 
 20 
Neutralization Assay. 21 
Two-fold serial dilutions of heat (56°C) inactivated mouse sera were mixed and pre-incubated with 22 
100 times the 50% tissue culture infectious dose (TCID50) of each indicated virus per well of a 96-23 
well plate in a final volume of 100 µl. The plates were then incubated for 1hr at 37°C. The serum-24 
 2 
virus mixture was then added onto monolayers of MDCK cells that had been seeded at a density of 25 
2X104 cells/well/100µl 18hrs earlier. Infection was allowed to proceed for 18-20hrs. The media was 26 
removed and the cells were washed with PBS and then fixed with 80% ice-cold acetone/PBS. 27 
Infections were detected by incubation with a rabbit polyclonal anti-NP antibody. Positive wells 28 
were visualized by utilizing a secondary antibody labeled with peroxidase and the plates read in a 29 
plate reader. Neutralizing titers were determined as the highest dilution that displayed neutralization 30 
activity. 31 
  32 
 3 
 33 
 34 
Figure S1. HA/NP ratio in virions of glycosylation mutant viruses. Viruses (WT, 144, 144-172, 35 
71-142-177, 71-142-172-177) were grown in MDCK cells and purified by ultracentrifugation 36 
through a 20% sucrose cushion. The viruses were deglycosylated by PNGaseF treatment and 37 
analysed by SDS-Page. Coomassie stained gels were used to quantify the HA1 band in comparison 38 
to the NP band for each virus. The average ratio from three independent gels is graphed. 39 
  40 
 4 
 41 
Figure S2. Sensitivity of the glycosylation mutant viruses to the Oseltamivir antiviral. A. 42 
Neth/09 glycosylation mutant viruses do not differ from WT in their sensitivity to Oseltamivir in an 43 
in vitro assay. Log dose inhibition curves for the WT Neth/09 and the 144, 144-172, 71-142-177 44 
and 71-142-172-177 viruses were determined in an NA Star chemiluminescent substrate cleavage 45 
assay. Data points represent the average number of relative fluorescent units (RLU) at each drug 46 
concentration (0-1000nM in 3-fold dilutions), expressed as a percentage of the RLUs obtained in 47 
the absence of drug; error bars indicate standard deviations. 2B. Glycosylation mutant viruses show 48 
minor differences in their sensitivity to Oseltamivir in a tissue culture replication assay. MDCK 49 
were infected with the different viruses at an MOI of 0.1 in the presence of different concentrations 50 
of Oseltamivir (0, 10 and 100 nM). Supernatants containing virus were harvested at 24h post 51 
infection and virus titers were determined on MDCK cells by standard plaque assay. 52 
 5 
 53 
Figure S3: Neutralization activity of sera from mice infected with rWT and 144 glycosylation 54 
mutant viruses. Sera from mice infected with either rWT or a virus containing glycosylation 144, 55 
obtained at day 28 p.i. were analyzed by micro-neutralization assays. Titers represent the 56 
geometrical mean of the highest dilution that displayed neutralization activity. 57 
  58 
 6 
 59 
Figure S4: Pathogenesis of Neth/09 viruses containing single and double glycosylations. 60 
Additional viruses containing single or double glycosylations were generated to evaluate their 61 
individual contribution to virulence and cross-reactivity (or lack of) seen with the viruses containing 62 
the multiple glycsylations.  8-week-old C57B/6 female mice were infected with 1X104 pfu of each 63 
of the indicated viruses and the average body weight of mice n=5 per group was determined for 15 64 
days. Error bars denote the s.d. for each time point. Mice were allowed to seroconvert for 29 days, 65 
and convalescent sera were used to test their HI activity against the virus containing the naturally 66 
occurring glycosylations. Results are shown in Table 2. 67 
  68 
 7 
 69 
Figure S5: Pathogenesis of Tx91 viruses containing glycosylation deletions by alternative 70 
mutations. To fully evaluate the contribution of glycosylations in cross reactivity, we generated 71 
Tx91 glycosylation mutants that removed the glycosylation motif and introduced a non-relevant 72 
amino acid within or close to the antigenic site (amino acid changes are shown). 8-week-old 73 
C57B/6 female mice were infected with 1X104 pfu of each of the indicated viruses and average 74 
body weights of mice n=5 per group were obtained for 15 days. Error bars denote the s.d. for each 75 
time point. Mice were allowed to seroconvert and were then challenged at 29 days p.i with 76 
100LD50 of WT Neth/09. Results are shown in Fig 6.  77 
78 
 8 
Table S1. HAI titers of adult and pediatric human sera after vaccination with 2009 pH1N1 79 
inactivated vaccine. 80 
 81 
 9 
a Human serum samples obtained on days 0 (Pre) and 42  (Post) after vaccination, respectively. 82 
Subjects received the 2009 H1N1 inactivated vaccine on days 0 and 21. 83 
b Human serum samples obtained on days 0 (Pre) and 21 (Post) after vaccination, respectively. 84 
Subjects received the 2009 H1N1 inactivated vaccine on day 0 only. 85 
c Human serum samples obtained on days 0 (Pre) and 42 (Post) after vaccination, respectively. The 86 
2009 TIV: trivalent inactivated influenza virus vaccine which included strains A/Brisbane/57/2007 87 
(H1N1), A/Brisbane/10/2007 (H3N2) and B/Brisbane/60/2008, was given on day 0 and the 2009 88 
H1N1 vaccine was given on day 21. 89 
d Human serum samples obtained on days 0 (Pre) and 63 (Post) after vaccination, respectively. 2009 90 
H1N1 inactivated vaccine was given on days 0 and 21 and the 2009 TIV: trivalent inactivated 91 
influenza virus vaccine, which included strains A/Brisbane/57/2007 (H1N1), A/Brisbane/10/2007 92 
(H3N2) and B/Brisbane/60/2008, was given on day 42. 93 
